Literature DB >> 11055242

Empty virus-like particle-based enzyme-linked immunosorbent assay for antibodies to hepatitis E virus.

T C Li1, J Zhang, H Shinzawa, M Ishibashi, M Sata, E E Mast, K Kim, T Miyamura, N Takeda.   

Abstract

Hepatitis E, an enterically transmitted non-A, non-B hepatitis, is a serious viral infection that occasionally causes large epidemics in developing countries. In developed countries, the disease only appears sporadically due to the transmission routes, and it is considered to be less important. The hepatitis E virus (HEV) cannot grow in cultured cells and no reliable assay system has ever been developed. In addition, the present diagnostic are not perfect, and actual rates of HEV infection may be underestimated. Highly purified empty virus-like particles (VLPs) of HEV have been produced by the use of a recombinant baculovirus vector in insect cells. Using these VLPs as an antigen, an enzyme-linked immunosorbent assay (ELISA) for antibodies to HEV was developed. A panel of 164 sera that were randomized and coded, and sera collected periodically from three patients with hepatitis E were used for the evaluation. The sensitivity of the assay was shown to be equal to or better than that obtained in previous research that used the same serum panel. The ELISA demonstrated that the serum IgM level of the patients was highest at the onset of the clinical illness and then rapidly decreased. In contrast, a high level of circulating IgG antibody titers lasted for more than 4 years. In Japan, a non-endemic country, the prevalence of the IgG class antibody to HEV in healthy individuals was found to range from 1.9% to 14.1%, depending on the geographical area. Only one out of 900 (0.1%) serum samples was IgM-positive. The IgM class antibody to HEV was detected in 10.8% of non-A, non-B, and non-C acute hepatitis patients in northeast China, whereas none of the patients in Korea had the IgM antibody. The ELISA utilizing the VLPs is sensitive and specific in its detection of the IgM and IgG antibodies to HEV. The ELISA is therefore useful for diagnosing HEV infection and for seroepidemiological study of hepatitis E.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11055242     DOI: 10.1002/1096-9071(200011)62:3<327::aid-jmv4>3.0.co;2-1

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  18 in total

1.  Virological, serological, and clinical features of an outbreak of acute gastroenteritis due to recombinant genogroup II norovirus in an infant home.

Authors:  Takeshi Tsugawa; Kazuko Numata-Kinoshita; Shinjiro Honma; Shuji Nakata; Masatoshi Tatsumi; Yoshiyuki Sakai; Katsuro Natori; Naokazu Takeda; Shinichi Kobayashi; Hiroyuki Tsutsumi
Journal:  J Clin Microbiol       Date:  2006-01       Impact factor: 5.948

Review 2.  Small Animal Models of Hepatitis E Virus Infection.

Authors:  Tian-Cheng Li; Takaji Wakita
Journal:  Cold Spring Harb Perspect Med       Date:  2019-08-01       Impact factor: 6.915

3.  Detection of sporadic cases of hepatitis E virus (HEV) infection in China using immunoassays based on recombinant open reading frame 2 and 3 polypeptides from HEV genotype 4.

Authors:  Y Wang; H Zhang; Z Li; W Gu; H Lan; W Hao; R Ling; H Li; T J Harrison
Journal:  J Clin Microbiol       Date:  2001-12       Impact factor: 5.948

4.  Simultaneous detection of immunoglobulin A (IgA) and IgM antibodies against hepatitis E virus (HEV) Is highly specific for diagnosis of acute HEV infection.

Authors:  Masaharu Takahashi; Shigeyuki Kusakai; Hitoshi Mizuo; Kazuyuki Suzuki; Kuniko Fujimura; Kazuo Masuko; Yoshiki Sugai; Tatsuya Aikawa; Tsutomu Nishizawa; Hiroaki Okamoto
Journal:  J Clin Microbiol       Date:  2005-01       Impact factor: 5.948

Review 5.  Hepatitis E: an overview and recent advances in vaccine research.

Authors:  Ling Wang; Hui Zhuang
Journal:  World J Gastroenterol       Date:  2004-08-01       Impact factor: 5.742

6.  Polyphyletic strains of hepatitis E virus are responsible for sporadic cases of acute hepatitis in Japan.

Authors:  Hitoshi Mizuo; Kazuyuki Suzuki; Yasuhiro Takikawa; Yoshiki Sugai; Hajime Tokita; Yoshihiro Akahane; Keiichi Itoh; Yuhko Gotanda; Masaharu Takahashi; Tsutomu Nishizawa; Hiroaki Okamoto
Journal:  J Clin Microbiol       Date:  2002-09       Impact factor: 5.948

7.  Clinical and epidemiological relevance of quantitating hepatitis E virus-specific immunoglobulin M.

Authors:  Jitvimol Seriwatana; Mrigendra P Shrestha; Robert M Scott; Sergei A Tsarev; David W Vaughn; Khin Saw Aye Myint; Bruce L Innis
Journal:  Clin Diagn Lab Immunol       Date:  2002-09

8.  Autochthonous hepatitis E in Southwest England: a comparison with hepatitis A.

Authors:  H R Dalton; W Stableforth; S Hazeldine; P Thurairajah; R Ramnarace; U Warshow; S Ijaz; V Ellis; R Bendall
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-02-26       Impact factor: 3.267

Review 9.  Hepatitis E vaccines: progress and prospects.

Authors:  Harald Claus Worm; Gerhard Wirnsberger
Journal:  Drugs       Date:  2004       Impact factor: 9.546

10.  Epidemiology of hepatitis E virus in the United States: results from the Third National Health and Nutrition Examination Survey, 1988-1994.

Authors:  Mark H Kuniholm; Robert H Purcell; Geraldine M McQuillan; Ronald E Engle; Annemarie Wasley; Kenrad E Nelson
Journal:  J Infect Dis       Date:  2009-07-01       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.